Laboratorio de Biología Molecular, Cátedra de Genética y Biología Molecular, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Clin Endocrinol (Oxf). 2012 Apr;76(4):568-76. doi: 10.1111/j.1365-2265.2011.04249.x.
Iodide organification defect (IOD) is characterized by a reduced ability of the thyroid gland to retain iodide resulting in hypothyroidism. Mutations in thyroid peroxidase (TPO) gene appear to be the most common cause of IOD and are commonly inherited in an autosomal recessive fashion. The TPO gene is located on the chromosome 2p25. It comprises 17 exons, covers approximately 150 kb of genomic DNA and codes 933 amino acids.
In this study, we characterize the clinical and molecular basis of seven patients from four unrelated families with congenital hypothyroidism (CH) because of IOD.
All patients underwent clinical, biochemical and imaging evaluation. The promoter and the complete coding regions of the human TPO along with the flanking intronic regions were analysed by single-strand conformation polymorphism analysis and direct DNA sequencing. Segregation analysis of mutations was carried out, and the effect of the novel missense identified mutations was investigated by 'in silico' studies.
All subjects had congenital and persistent primary hypothyroidism. Three novel mutations: c.796C>T [p.Q266X], c.1784G>A [p.R595K] and c.2000G>A [p.G667D] and a previously reported mutation: c.1186_1187insGGCC [p.R396fsX472] have been identified. Four patients were compound heterozygous for p.R396fsX472/p.R595K mutations, two patients were homozygous for p.R595K, and the remaining patient was a compound heterozygous for p.Q266X/p.G667D.
Our findings confirm the genetic heterogeneity of TPO defects and the importance of the implementation of molecular studies to determinate the aetiology of the CH with dyshormonogenesis.
碘有机化缺陷(IOD)的特征是甲状腺保留碘的能力降低,导致甲状腺功能减退。甲状腺过氧化物酶(TPO)基因的突变似乎是 IOD 的最常见原因,通常以常染色体隐性遗传方式遗传。TPO 基因位于 2p25 染色体上。它由 17 个外显子组成,覆盖大约 150kb 的基因组 DNA,编码 933 个氨基酸。
本研究对 4 个无关家系的 7 例先天性甲状腺功能减退症(CH)患者的临床和分子基础进行了研究。
所有患者均进行临床、生化和影像学评估。采用单链构象多态性分析和直接 DNA 测序法分析人 TPO 的启动子和完整编码区以及侧翼内含子区。进行突变的分离分析,并通过“计算机模拟”研究调查新发现的错义突变的影响。
所有患者均患有先天性和持续性原发性甲状腺功能减退症。发现了 3 个新突变:c.796C>T [p.Q266X]、c.1784G>A [p.R595K]和 c.2000G>A [p.G667D],以及一个先前报道的突变:c.1186_1187insGGCC [p.R396fsX472]。4 例患者为 p.R396fsX472/p.R595K 突变的复合杂合子,2 例患者为 p.R595K 的纯合子,其余患者为 p.Q266X/p.G667D 的复合杂合子。
本研究结果证实了 TPO 缺陷的遗传异质性,以及实施分子研究以确定伴有激素生成障碍的 CH 病因的重要性。